First successful case of platinum-based chemotherapy for neuroendocrine prostate cancer with BRCA2 and PTEN alterations.

INTRODUCTION: Deoxyribonucleic acid repair gene mutations are now being studied in a variety of solid tumors, with the hope of predicting prognosis, pathogenesis, and treatment outcomes. CASE
PRESENTATION: We report the case of a Japanese patient with advanced castration-resistant prostate cancer who exhibited a prominent response to platinum therapy and had coexisting BRCA2 and PTEN mutations according to retrospective multigene panel analysis.
CONCLUSION: Through a review of clinical outcomes and genetic/pathologic profiling, the presented case provides insights into future management strategies based on the tumor genetic status.

androgen receptor

carboplatin

cabazitaxel

castration‐resistant prostate cancer

estimated copy number

deoxyribonucleic acid

docetaxel

double‐strand break

luteinizing hormone‐releasing hormone

neuron specific enolase

prostate‐specific antigen

transurethral resection of the prostate

etoposide

We present a Japanese patient with CRPC and coexisting BRCA2 and PTEN mutations who displayed a prominent response to platinum therapy. The patient exhibited atypically long survival despite high‐risk clinical and pathological features, and the relationships of disease progression and treatment response with the genetic status were explored. Our study provides insights into future management strategies based on the tumor genetic status.

Introduction

DNA repair gene mutations have been studied in a variety of solid tumors and are now gathering attention in prostate cancer because of the possible effects on outcome and selection of treatment. Since June 2019 in Japan, a gene panel analysis system under the name of OncoGuide NCC Oncopanel System and FoundationOne has been listed for coverage under the national health insurance and has provided opportunities to review atypical clinical outcomes in patients with cancer. In this report, we presented a case of long‐surviving CRPC with a prominent response to initial platinum therapy in a patient carrying a rare combination of somatic BRCA2 and PTEN mutations.

Case presentation

A 67‐year‐old man presented with an elevated PSA level (7.08 ng/mL) and signs of prostate enlargement on ultrasound during follow‐up of chronic hepatitis. Transrectal prostate needle biopsy revealed a pathologic diagnosis of adenocarcinoma with Gleason score of 4 + 5 = 9 in 9 of 12 specimens. Based on post‐biopsy images, the patient was staged as cT3bN1M1a with seminal vesicle involvement and lymphadenopathy within the left obturator fossa, paraaortic, supraclavicular, and mediastinal regions. Subsequently, he received combined androgen blockade therapy. After 27 months, a new metastasis to the rib was detected on bone scintigraphy, although his PSA level was controlled at 0.86 ng/mL (Fig. 1). As his PSA level reached 7.28 ng/ mL, based on a diagnosis of CRPC, the treatment was altered to abiraterone.

Fig. 1

(a) Serum PSA level, NSE level and treatment time course of the study patient computed tomography and magnetic resonance imaging show response to therapy. (a) Low power view of tumor tissue stained with hematoxylin and eosin. Tissue immunostaining to detect (b) PSA, (c) synaptophysin, (d) AR, and (e) PTEN. The scale bar indicates 100 μm.

During abiraterone treatment, the patient’s PSA level increased accompanying elevation of neuron‐specific enolase and urination disorder secondary to obstruction. He underwent TUR, and the specimen displayed adenocarcinoma (Gleason score 5 + 5 = 10) with synaptophysin‐positive cells. Thus, he was diagnosed as adenocarcinoma with neuroendocrine differentiation (Fig. 1). Subsequent immunohistochemistry of his initial biopsy specimen revealed minor portions of synaptophysin‐ and chromogranin A‐positive cells.

Considering these results, platinum‐based treatment in combination with etoposide was selected (Fig. 1). After 11 courses, his serum PSA level decreased and his lymph nodes regressed. Owing to this drastic response, treatment was continued for 17 months, at which point his PSA level had increased to 22.53 ng/mL and lymphadenopathy recurred. The treatment was changed to DOC and then to CBZ because of PSA elevation, but the patient died before the approval and availability of olaparib.

After the approval of FoundationOne CDx, we performed next‐generation sequencing using his TUR specimen while the patient was still undergoing platinum‐based chemotherapy (Appendix S1; Table S1). All gene alterations are provided in Table S2. There were large deletions in BRCA2 (exons 1–11) and PTEN (exons 2–3) accompanying biallelic loss (eCN was calculated as 0). TP53 somatic frameshift mutation (p.A86fs*55) and FANCA somatic frameshift mutation (p.S849fs*40) were detected as a pathogenic variant in the tumor. Furthermore, AR gene amplification revealed an eCN of 10. Several other gene mutations were detected as a variant of unknown significance. The tumor mutation burden in the sample was 8.8 single nucleotide variants/Mbp.

Sequencing and immunohistochemistry were performed for both the tumor and intact regions, revealing large deletions in BRCA2 and PTEN only in the tumor. The normal copy numbers of BRCA2 and PTEN in normal prostatic tissue implied that these mutations were somatic events. The tumor cells showed reduced staining for PTEN, suggesting loss of expression at the protein level (Fig. 1).

Discussion and conclusions

BRCA2 is a tumor suppressor gene known for its role in the repair of DNA DSBs. Loss of BRCA2 function leads to the failure of homologous recombination, making cells vulnerable to damage. Among patients with prostate cancer, up to 16.3% are reported to carry either germline or somatic BRCA2 mutations. Germline BRCA2 mutation is more common in metastatic hormone‐naïve prostate cancer than in localized disease (5.35% vs 0.87%). Moreover, patients with early‐onset prostate cancer have a relatively high rate of BRCA2 mutation. ,

In ovarian and breast cancers, the presence of BRCA2 mutation was mentioned to confer possible sensitivity to platinum agents and poly‐ADP ribose polymerase inhibitors. , , These agents are known to induce intrastrand and interstrand DNA damage, and similar responses are expected in prostate cancer. ,

Conversely, PTEN is a tumor suppressor gene known to inhibit signaling pathways related with tumor growth and migration. The loss of PTEN function was detected in up to 20% of primary prostate tumor samples obtained via radical prostatectomy, , , , and its frequency increased to as high as 50% in CRPC. Among patients treated with abiraterone, those with PTEN loss are known to have higher incidence of metastatic disease and significantly lower survival rates. Studies on treatment targeting the AKT signaling pathway are ongoing.

As mentioned previously, BRCA2 and PTEN mutations are commonly observed in advanced CRPC. However, to our surprise, we found that BRCA2 and PTEN alterations were mutually exclusive in both primary and advanced , cancers (Table S3). Of the 333 primary and 150 advanced cases, only one case in each cohort displayed coexistent BRCA2 and PTEN gene alterations (Table S3). The BRCA2 and PTEN alterations were linked to features such as Gleason score 8 (4 + 4), T3a adenocarcinoma, and mortality within 4.8 months in the primary prostate cancer case (Table S4). Considering these findings, patients with coexistent BRCA2 and PTEN alteration tend to have poor prognosis.

Clinically, our patient rapidly developed high‐grade metastatic disease, exhibiting a limited response to abiraterone. Pathologically, the patient was diagnosed with prostate cancer with neuroendocrine differentiation and displayed long survival after treatment with platinum agents. Through genome sequencing, we were able to discover the presence of somatic BRCA2 and PTEN alterations in the background of the disease. The prominent response to platinum agents may be explained by loss of BRCA2 function and vulnerability to DSBs. However, the mechanism of the later resistance to platinum‐based chemotherapy remains an unanswered question. The frequency of somatic BRCA2 and PTEN alterations in patients with neuroendocrine prostate cancer is unknown because of its rarity and the lack of available genomic analysis in the literature.

This patient unfortunately died before the approval of olaparib. If this treatment had been available, it would have likely been used in the first‐line setting in our patient. However, the outcome of this treatment would have been unpredictable. As gene panel analysis becomes accessible for daily practice, the accumulation of data is expected. As a first step, we reported a Japanese patient with neuroendocrine CRPC with coexistent somatic BRCA2 and PTEN alterations displaying a prominent response to platinum therapy. Our retrospective report hopes to shed light on improving the survival of patients with high‐risk disease through adequate treatment selection based on early gene profiling.

Funding

This work was supported in part by a Grant‐in‐Aid for Scientific Research (B: #20H03817 to TK) from the Ministry of Education, Culture, Sports, Science and Technology of Japan. The work was supported in part by a research grant to T. Kosaka from Keio Gijuku Fukuzawa Memorial Fund for the Advancement of Education and Research, Japan.

Author contributions

Conception and design of the study: TK, MO, KN. Acquisition and analysis of data: TK, EA, HH, SM, KN, and HN. Drafting the manuscript and figures: TK, SM, HN, and MO. KN and HN were responsible for targeted next‐generation sequencing. Drafting the manuscript and figures: TK, SM, HN, and MO. All authors read and approved the final version of this manuscript.

Conflict of interest

The authors declare no conflict of interest.

Approval of the research protocol by an Institutional Reviewer Board

The study was approved by the by the Ethics Committee of Keio University Hospital (Approval numbers: 20160084 and 20180015).

Informed consent

Consent to participate and for publication were acquired from the patient.

Consent for publication

Consent for publication was acquired from the patient.

Registry and the Registration No. of the study/trial

Not applicable.

Table S1. 160 genes examined in the PleSSision‐Rapid test.

Click here for additional data file.

Table S2. Gene alterations in the study patient.

Click here for additional data file.

Table S3. Co‐occurrence of BRCA2 and PTEN alterations analyzed using The Cancer Genome Atlas cohort data (a) and The SU2C−Prostate Cancer Foundation Prostate Dream Team cohort data (b).

Click here for additional data file.

Table S4. Characteristics of the BRCA2 / PTEN co‐alteration case in The Cancer Genome Atlas cohort.

Click here for additional data file.

Appendix S1. Materials and Methods for gene panel analysis

Click here for additional data file.